17 Aug 2017 Pfizer Receives U.S. FDA Approval for BESPONSA® (inotuzumab ozogamicin)
17 Aug 2017 FDA Accepts Supplemental Biologics License Application and Grants Priority Review for ADCETRIS® (Brentuximab Vedotin) in Cutaneous T-Cell Lymphoma
17 Aug 2017 Aptevo Therapeutics and Alligator Bioscience Commence IND-Enabling Development Activities for New Bispecific Immunotherapy Candidate ALG.APV-527
16 Aug 2017 Bristol-Myers Squibb Announces Topline Results from CheckMate -214, a Phase 3 Study of Opdivo in Combination with Yervoy in Intermediate and Poor-Risk Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
14 Aug 2017 Regeneron to Discontinue Development of Suptavumab for Respiratory Syncytial Virus
11 Aug 2017 Biotecnol and CRUK to Trial New Immuno-Oncology Treatment for Advanced Solid Tumours
08 Aug 2017 FibroGen Announces Positive Topline Results from Phase 2 Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis
03 Aug 2017 FDA Advisory Committee Does Not Recommend Approval Of Sirukumab For The Treatment Of Moderately To Severely Active Rheumatoid Arthritis
02 Aug 2017 Aridis Pharmaceuticals Enrolls First Patients in Global Pivotal Clinical Trial of Novel Monoclonal Antibody for Treating Acute Pneumonia
01 Aug 2017 Glenmark Pharmaceuticals Reports Positive Data in a Phase 2a Study of GBR 830 for the Treatment of Patients with Atopic Dermatitis
01 Aug 2017 Bristol-Myers Squibb Receives FDA Approval for Opdivo (nivolumab) in MSI-H or dMMR Metastatic Colorectal Cancer That Has Progressed Following Treatment with a Fluoropyrimidine, Oxaliplatin, and Irinotecan
01 Aug 2017 Acceleron Announces First Patient Treated in Phase 2 Clinical Trial of ACE-083 in Charcot-Marie-Tooth Disease
31 Jul 2017 Amgen Submits Supplemental Biologics License Application For Prolia® (denosumab) In Glucocorticoid-Induced Osteoporosis
31 Jul 2017 Amgen And Allergan Submit Biosimilar Biologics License Application For ABP 980 To US Food And Drug Administration
31 Jul 2017 Celltrion and Teva Announce U.S. FDA Acceptance of Biologics License Application for Proposed Biosimilar to Herceptin® (trastuzumab)
31 Jul 2017 Imfinzi granted Breakthrough Therapy Designation by US FDA for patients with locally-advanced unresectable non-small cell lung cancer
29 Jul 2017 Publication of Research Article on Foralumab, a Fully Human Anti-CD3 Antibody Being Developed as an Oral Therapy for NASH and Autoimmune Diseases
29 Jul 2017 Galderma Announces Enrollment of First Patient in Phase IIb Nemolizumab Trial in Atopic Dermatitis
29 Jul 2017 FDA Grants Priority Review For Amgen's Supplemental Biologics License Application For Repatha® (evolocumab) To Include Data On Reducing Risk Of Cardiovascular Events
27 Jul 2017 Boehringer Ingelheim starts clinical study on interchangeability between its adalimumab biosimilar candidate and HUMIRA®
27 Jul 2017 Compugen Discloses Updates to Collaborative Activities with Bayer in Immuno-Oncology
27 Jul 2017 AstraZeneca reports initial results from the ongoing MYSTIC trial in Stage IV lung cancer
26 Jul 2017 First Patient Enrolled in OncoQuest's Phase 1/2 Study Combining Oregovomab with Hiltonol® in Recurrent Ovarian Cancer
26 Jul 2017 Bristol-Myers Squibb’s ORENCIA® (abatacept) Receives Second European Commission Approval in Less than a Year – New Approval for Treatment of Active Psoriatic Arthritis (PsA)1
26 Jul 2017 Santen and TRACON Announce Initiation of a Phase 2a Study of DE-122 for the Treatment of Wet Age-Related Macular Degeneration

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing